Patients and Methods This phase II trial enrolled patients with documented non–small-cell lung cancer, clinically staged IB-IIIA, and considered candidates for surgical resection. Postchemotherapy mediastinal-based treatment decisions allow for in vivo testing of activity and could help to determine the ideal local treatment. ![]() Incorporation of new active drugs in the neoadjuvant treatment of operable patients might lead to improved outcomes. TL DR: Localized non-small-cell lung cancer is very sensitive to chemotherapy and postchemotherapy mediastinal-based treatment decision led to a high complete resection rate, even in patients with large tumors.Ībstract: Purpose Lung cancer is an epidemic disease in developing countries.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |